GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride

Phase 1

Completed

Conditions: Hypogonadism
Hypogonadism, Male

First Posted Date: 2006-11-16

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT00400335

Locations: 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg

First Posted Date: 2006-11-14

Last Posted Date: 2018-01-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 648

Registration Number: NCT00398645

Locations: 🇺🇦
GSK Investigational Site, Vinnitsa, Ukraine

28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men

Phase 2

Completed

Conditions: Hypogonadism
Hypogonadism, Male

First Posted Date: 2006-11-10

Last Posted Date: 2017-05-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 43

Registration Number: NCT00398580

Locations: 🇺🇸
GSK Investigational Site, Seattle, Washington, United States

Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV-1 Infection

First Posted Date: 2006-11-10

Last Posted Date: 2012-07-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00398125

Locations: 🇺🇸
GSK Investigational Site, Dallas, Texas, United States

Fluticasone Nasal Spray Patient Preference Study

Phase 3

Completed

Conditions: Rhinitis, Allergic, Perennial

Interventions: Drug: fluticasone propionate (FP)
Drug: fluticasone furoate (FF)

First Posted Date: 2006-11-10

Last Posted Date: 2018-03-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 127

Registration Number: NCT00398476

Locations: 🇺🇸
GSK Investigational Site, El Paso, Texas, United States

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Biological: GSK's candidate Mycobacterium tuberculosis vaccine 692342
Biological: Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system
Biological: Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline
Biological: Control vaccine with the adjuvant system.